Cystic fibrosis is frequently accompanied by a catabolic condition with low body mass index caused by a number of disease complications. Insulin-like growth factor-I (IGF-I) is an anabolic hormone and an important marker of nutritional status, liver function, and linear growth. Available data on IGF-I in cystic fibrosis are sparse and conflicting. From 1990-3, 235 of our 240 patients (114 males, 121 females, median age 16-2 years, range 0-1-44-0 years) had IGF-I measured once by radioimmunoassay. IGF-I was significantly reduced compared with a healthy Scandinavian control population: mean (-2 SD to +2 SD) IGF-I SD score was -0-97 (-3.7 to 1.7) in males and -0-67 (-3.2 to 1.9) in females.
Cystic fibrosis is the most common serious disease with autosomal recessive inheritance and the incidence in Denmark is 1:4761.1 In younger patients the disease is usually well controlled with intensive, prophylactic, antibiotic treatment and pancreatic enzyme substitution. However, with increasing age and progression of the lung disease, patients with cystic fibrosis experience increasing catabolic problems with loss of weight and decline in body mass index (BMI). Several reasons for this catabolic condition are obvious and include chronic pulmonary infection with Pseudomonas aeruginosa and other pseudomonas species, diabetes mellitus, and impairment of liver function.
Changes in the concentration of insulinlike growth factor-I (IGF-I) might play a part in patients with cystic fibrosis. IGF-I is an anabolic hormone that stimulates the formation of bone and cartilage, and has an insulin-like effect.2 The production of IGF-I takes place primarily in the liver, and the concentration in the blood is mainly regulated by growth hormone. However, other factors also play a part in the regulation including nutritional status, liver function, and concentrations of sex steroids.2 3 Results of earlier studies on IGF-I in small groups of patients with cystic fibrosis have been conflicting as both normal and diminished concentrations have been reported.4-7 As the first step in the elucidation of the significance of IGF-I in cystic fibrosis, we performed a cross sectional study to determine the serum concentrations of IGF-I in a large, unselected population of patients and correlated the results to genotype and simple measures of growth, nutrition, pulmonary function, and liver function. IGF-I SD score -0 97* -0-67* -0Q57* -1-37* -0-69* -0-13 -0-96* -0-84** (-37to 1-7)
Patients and methods
(-3-2to 1 9) (-2-3to 1-1) (-4-2to 1-4) (-5-8to34) (-2-2to 1-9) (-3-1 to 1-2) (-39to22) Height SD score -0 95* -0-81* -1-04* -0 91* -0-92* -0-65** -0-84* -0 90* (-2-1 to 1-4) (-3-2 to 1-6) (-3-6 to 1-5) (-33 to 1-4) (-3-1 to 1-3) (-3-2 to 19) (-3-1 to 1-4) (-33 to 1-5)
Different from zero: *p<0.001; **p<0 01.
STATISTICS
Statistical analyses were performed using a statistical package (SPSS/PC+). Student group of patients with cystic fibrosis. Furthermore, as a group the cystic fibrosis patients were significantly growth retarded and 17% were below -2 SD for height. The correlation between IGF-I and height was significant but rather weak. However, this is also the case in normal controls,8 as short term changes may occur, for example, due to acute infections or decreased food intake. Previous studies in patients with cystic fibrosis have yielded conflicting results as three studies in 31, 19, and 15 patients, respectively, revealed normal concentrations of IGF-I compared with normal controls.4 6 7 Furthermore, Rosenfeld et al found no correlation between IGF-I and height.7 In contrast, Lee et al showed a 50% decrease in IGF-I concentrations compared with normal controls in six cystic fibrosis patients with severe growth retardation.5 According to the age groups shown in the table, the most pronounced deviations in IGF-I concentrations in our study were found in individuals between the age of 10 and 20 years where peak values occur. Many patients with cystic fibrosis enter puberty late causing a delayed pubertal peak in IGF-I. According to this the reduction in IGF-I SD score would tend to be most pronounced during a delayed puberty. Furthermore, many children with cystic fibrosis develop chronic colonisation of the lungs with P aeroginosa during the pubertal years. The cumulative prevalence was reported to be 50% between 1 1 and 12 years in our patients.10 Finally, the development of impaired glucose tolerance often occurs in the pubertal years. We have previously shown that the incidence and prevalence of impaired glucose tolerance and diabetes mellitus increased with age, and from 15-30 years the decrease in normal glucose tolerance was almost linear."l The mean age of developing diabetes mellitus in the Danish cystic fibrosis patients was 15 years in females and 22 years in males (Lanng et al, unpublished  data) .
The type of mutation in cystic fibrosis has some influence on the expression of the disease.'0 The delta F508 mutation comprises 88% of Danish cystic fibrosis mutations which forms a rather uniform patient population' and fat malabsorption was present in different degrees in the vast majority of our cystic fibrosis patients.'2 Impaired nutritional status is known to be associated with lowering of IGF-I,2 and BMI SD score was reduced in the patients. However, BMI SD score only correlated weakly with IGF-I, indicating that malabsorption and insufficient energy intake were not responsible for the reduced IGF-I concentrations. Also Rosenfeld et al found no correlation of IGF-I with weight or nutritional status.7 Chronic and recurrent pulmonary infection and the subsequent decrease in pulmonary function lead to increased resting energy expenditure and weight loss, so the decline in BMI with age may be due to the progressive lung disease rather than being related to low IGF-I production. It is well known that the conventional liver function tests as used in this study do not express the degree of liver dysfunction in cystic fibrosis very well.'3 14 The liver disease in cystic fibrosis is primarily caused by obstruction in the bile system leading to the characteristic macronodular cirrhosis, '3 15 
